The BRCA Somatic test is designed to identify patients with inherited and
non-inherited BRCA1 and BRCA2 genes mutations that could benefit from
treatment with PARP inhibitors.
BRCA somatic test detects BRCA1 and BRCA2 gene mutations and identifies patients, who could benefit from treatment with PARP inhibitors.
These genes play an important role in the repair of damaged DNA, as they encode tumor suppressor proteins. The importance of these genes is that they encode tumor suppressor proteins. BRCA1 and BRCA2 gene mutations help to select the most appropriate individualised treatment.
PARP inhibitors inhibit the growth of cancer cells that carry mutations in the BRCA1 or BRCA2 genes. Specifically, they target Poly(ADP)Ribose Polymerases (PARP), which play a crucial role in repairing DNA damage. It has been shown that somatic BRCA genes mutations in patients with advanced ovarian and prostate cancer are biomarkers of patient’s response to PARP inhibitors.
BRCA Somatic test is carried out using the Oncomine BRCA assay on the Next Generation Sequencing platform Ion Proton (Thermo Fisher Scientific) which provides:
What types of cancer does it cover?
The test covers BRCA somatic mutations that have been detected in various solid tumors, more frequently in breast, ovarian, pancreatic and prostate cancer.
Why should I choose this test?
BRCA Somatic also detects somatic mutations, i.e. mutations found in the tumor. Thus, it can increase the percentage of patients with a detectable BRCA mutation who could benefit from treatment with PARP inhibitors. If a pathogenic mutation is detected, the analysis of genomicDNA from patient’s blood is recommended, in order to determinethe somatic or hereditary origin of the mutation.
If a pathogenic mutation is found, do I need additional tests?
If a pathogenic mutation is detected, genomic DNA analysis from the patient’s blood is recommended to determine the somatic or hereditary origin of the mutation. In case of a germline mutation the analysis of patient’s relatives for the particular mutation is also recommended.
If a pathogenic mutation is not found, do I need additional tests?
In case of suspected hereditary syndrome, the BRCA Germline test or the HerediGENE test is recommended.
In how many days will the results be available?
Results will be available in 15 business days.
What sample is required for the test?
A paraffin block which contains the tumor tissue or unstained paraffin slides (not in autoclave). More specifically, we need 4 sections of 3μm and 6 sections of 10μm.
Is the test covered by any public/private insurance?
The test is covered by EOPYY under specific conditions. For information, please contact us at +30 210 6032138. For information, please contact us at +30 210 6032138.
How do I make the payment for the test?
Payment can be made by bank transfer or debit/credit card.
How can I send my sample?
For the necessary sample collection procedures, please contact us at +30 210 6032138 .
Why should I sign the consent form?
For the use of the patient’s genetic material for testing, ELOT EN ISO9001:2008 and ELOT EN ISO15189:2012 require the written consent of each patient.
How will I receive my results?
Your results are shared with your GP via email.
Our Customer Service Team is committed to answer your questions with regards to the services offered by Genekor. If you would like to order any of the tests that Genekor performs please contact us directly.
*To complete the test, you are required to complete and send the Consent form that you will find on the link below.
*For more information on scientific content please contact: scientific.support@genekor.com
*Order in the United Arab Emirates here.